$SVRA
Savara Inc

2021 Q4 Form 10-Q Financial Statement

#000095017021004253 Filed on November 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $0.00 $0.00 $256.0K
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.019M $3.400M $5.380M
YoY Change 8.21% -36.8% 91.46%
% of Gross Profit
Research & Development $7.618M $6.532M $5.603M
YoY Change -25.02% 16.58% -41.48%
% of Gross Profit
Depreciation & Amortization $2.000K $40.00K -$270.0K
YoY Change -97.14% -114.81% -217.39%
% of Gross Profit
Operating Expenses $10.64M $9.972M $11.04M
YoY Change -18.22% -9.68% -11.26%
Operating Profit -$9.972M -$10.79M
YoY Change -7.54% -13.32%
Interest Expense -$642.0K -$566.0K -$459.0K
YoY Change -12.05% 23.31% -9280.0%
% of Operating Profit
Other Income/Expense, Net -$29.00K -$574.0K -$278.0K
YoY Change 106.47% -812.82%
Pretax Income -$11.31M -$10.55M -$11.06M
YoY Change -17.69% -4.65% -10.83%
Income Tax
% Of Pretax Income
Net Earnings -$11.31M -$10.55M -$11.06M
YoY Change -17.69% -4.67% -10.8%
Net Earnings / Revenue -4321.48%
Basic Earnings Per Share -$0.07
Diluted Earnings Per Share -$84.45K -$69.11K -$183.4K
COMMON SHARES
Basic Shares Outstanding 113.9M 152.6M
Diluted Shares Outstanding 152.6M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $161.2M $170.8M $94.30M
YoY Change 96.07% 81.13% -11.29%
Cash & Equivalents $34.01M $44.70M $35.20M
Short-Term Investments $127.2M $126.1M $59.10M
Other Short-Term Assets $2.685M $2.571M $1.500M
YoY Change 123.75% 71.4% 114.29%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $165.0M $174.6M $96.30M
YoY Change 93.84% 81.29% -11.08%
LONG-TERM ASSETS
Property, Plant & Equipment $73.00K $91.00K $500.0K
YoY Change -53.21% -81.8% -58.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $251.0K $1.052M $900.0K
YoY Change 0.4% 16.89% -45.49%
Total Long-Term Assets $11.60M $12.69M $13.00M
YoY Change -8.13% -2.38% -59.79%
TOTAL ASSETS
Total Short-Term Assets $165.0M $174.6M $96.30M
Total Long-Term Assets $11.60M $12.69M $13.00M
Total Assets $176.6M $187.3M $109.3M
YoY Change 80.67% 71.34% -22.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.443M $1.279M $1.700M
YoY Change -44.39% -24.76% -41.44%
Accrued Expenses $4.884M $5.215M $5.892M
YoY Change -12.46% -11.49% 9.35%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $8.333M $4.167M
YoY Change
Total Short-Term Liabilities $14.66M $10.66M $7.600M
YoY Change 79.35% 40.28% -8.43%
LONG-TERM LIABILITIES
Long-Term Debt $17.32M $21.35M $25.00M
YoY Change -31.0% -14.6% 0.0%
Other Long-Term Liabilities $117.0K $34.00K $100.0K
YoY Change 39.29% -66.0% -82.52%
Total Long-Term Liabilities $17.44M $21.38M $25.10M
YoY Change -30.76% -14.8% 4288.11%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.66M $10.66M $7.600M
Total Long-Term Liabilities $17.44M $21.38M $25.10M
Total Liabilities $32.10M $32.05M $32.70M
YoY Change -3.78% -2.0% -3.33%
SHAREHOLDERS EQUITY
Retained Earnings -$300.5M -$289.2M -$243.8M
YoY Change 16.7% 18.62% 38.39%
Common Stock $445.0M $444.2M
YoY Change 38.66%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $144.5M $155.2M $76.63M
YoY Change
Total Liabilities & Shareholders Equity $176.6M $187.3M $109.3M
YoY Change 80.67% 71.34% -22.28%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$11.31M -$10.55M -$11.06M
YoY Change -17.69% -4.67% -10.8%
Depreciation, Depletion And Amortization $2.000K $40.00K -$270.0K
YoY Change -97.14% -114.81% -217.39%
Cash From Operating Activities -$9.363M -$8.927M -$6.710M
YoY Change -23.88% 33.04% -41.24%
INVESTING ACTIVITIES
Capital Expenditures -$40.00K -$11.00K -$20.00K
YoY Change -45.0% 100.0%
Acquisitions
YoY Change
Other Investing Activities -$1.228M $12.99M -$6.850M
YoY Change 231.89% -289.69% -203.79%
Cash From Investing Activities -$1.268M $12.98M -$6.870M
YoY Change 233.68% -288.98% -204.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.000K 10.00K 1.830M
YoY Change -99.45% -67.95%
NET CHANGE
Cash From Operating Activities -9.363M -8.927M -6.710M
Cash From Investing Activities -1.268M 12.98M -6.870M
Cash From Financing Activities 6.000K 10.00K 1.830M
Net Change In Cash -10.63M 4.066M -11.75M
YoY Change -16.21% -134.6% -1435.23%
FREE CASH FLOW
Cash From Operating Activities -$9.363M -$8.927M -$6.710M
Capital Expenditures -$40.00K -$11.00K -$20.00K
Free Cash Flow -$9.323M -$8.916M -$6.690M
YoY Change -24.2% 33.27% -41.37%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
us-gaap:LicenseMember
dei Entity Central Index Key
EntityCentralIndexKey
0001160308
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
us-gaap:LicenseMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
us-gaap:LicenseMember
CY2020Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
us-gaap:LicenseMember
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-32157
dei Entity Registrant Name
EntityRegistrantName
Savara Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1318182
dei Entity Address Address Line1
EntityAddressAddressLine1
6836 Bee Cave Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Building III
dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 201
dei Entity Address City Or Town
EntityAddressCityOrTown
Austin
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78746
dei City Area Code
CityAreaCode
512
dei Local Phone Number
LocalPhoneNumber
614-1848
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
SVRA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
113868809
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44699000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22880000
CY2021Q3 us-gaap Short Term Investments
ShortTermInvestments
126107000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
59308000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3778000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2933000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
174584000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
85121000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
91000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
156000
CY2021Q3 svra In Process Research And Development
InProcessResearchAndDevelopment
11547000
CY2020Q4 svra In Process Research And Development
InProcessResearchAndDevelopment
12218000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1052000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
250000
CY2021Q3 us-gaap Assets
Assets
187274000
CY2020Q4 us-gaap Assets
Assets
97745000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1279000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2595000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5215000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5579000
CY2021Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
4167000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
10661000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8174000
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
21350000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
25104000
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
34000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
84000
CY2021Q3 us-gaap Liabilities
Liabilities
32045000
CY2020Q4 us-gaap Liabilities
Liabilities
33362000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
113866997
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
113866997
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54152955
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54152955
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
115000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
55000
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
444040000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
320893000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
285000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
942000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-289211000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-257507000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
155229000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
64383000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
187274000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
97745000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
256000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
256000
CY2021Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
6532000
CY2020Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
5603000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
21373000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
24881000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3400000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5375000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9331000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11474000
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
40000
CY2020Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
63000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
134000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
189000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
9972000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
11041000
us-gaap Operating Expenses
OperatingExpenses
30838000
us-gaap Operating Expenses
OperatingExpenses
36544000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9972000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10785000
us-gaap Operating Income Loss
OperatingIncomeLoss
-30838000
us-gaap Operating Income Loss
OperatingIncomeLoss
-36288000
CY2021Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-566000
CY2020Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-459000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1717000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-952000
CY2021Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-8000
CY2020Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
148000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-22000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
354000
CY2021Q3 svra Tax Credit Income
TaxCreditIncome
0
CY2020Q3 svra Tax Credit Income
TaxCreditIncome
-27000
svra Tax Credit Income
TaxCreditIncome
873000
svra Tax Credit Income
TaxCreditIncome
896000
CY2021Q3 svra Change In Fair Value Of Financial Instruments Net Of Contingent Consideration
ChangeInFairValueOfFinancialInstrumentsNetOfContingentConsideration
0
CY2020Q3 svra Change In Fair Value Of Financial Instruments Net Of Contingent Consideration
ChangeInFairValueOfFinancialInstrumentsNetOfContingentConsideration
60000
svra Change In Fair Value Of Financial Instruments Net Of Contingent Consideration
ChangeInFairValueOfFinancialInstrumentsNetOfContingentConsideration
0
svra Change In Fair Value Of Financial Instruments Net Of Contingent Consideration
ChangeInFairValueOfFinancialInstrumentsNetOfContingentConsideration
116000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-574000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-278000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-866000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
414000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-10546000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-11063000
us-gaap Net Income Loss
NetIncomeLoss
-31704000
us-gaap Net Income Loss
NetIncomeLoss
-35874000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.61
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
152587848
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
60288993
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
127623824
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
58842436
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-297000
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
289000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-645000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
323000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-10000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-156000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-12000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-53000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10853000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10930000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32361000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35604000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
64383000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
121827000
CY2021Q1 svra Adjustment To Additional Paid In Capital Repurchase Of Pre Funded Warrants
AdjustmentToAdditionalPaidInCapitalRepurchaseOfPreFundedWarrants
3909000
CY2021Q1 svra Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
2546000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
946000
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-431000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-26000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-10217000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
175121000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
321000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
771000
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
83000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
24000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-10941000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
165382000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
690000
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-297000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-10000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-10546000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
155229000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
101698000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
48000
CY2020Q1 svra Adjustments To Additional Paid In Capital Closing Costs For Previous Issuance Of Securities In Private Placement
AdjustmentsToAdditionalPaidInCapitalClosingCostsForPreviousIssuanceOfSecuritiesInPrivatePlacement
120000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
28000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1194000
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-128000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
17000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-15421000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
87316000
CY2020Q2 svra Stock Issued During Period Value Licensing Of Assets
StockIssuedDuringPeriodValueLicensingOfAssets
2120000
CY2020Q2 svra Issuance Of Common Stock Upon At The Market Offering Net
IssuanceOfCommonStockUponAtTheMarketOfferingNet
2290000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
39000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1175000
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
162000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
85000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-9389000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
83798000
CY2020Q3 svra Stock Issued During Period Value Issuance Of Common Stock Upon Exercise Of Milestone Warrants Net
StockIssuedDuringPeriodValueIssuanceOfCommonStockUponExerciseOfMilestoneWarrantsNet
1827000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1931000
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
289000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-156000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-11063000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
76626000
us-gaap Profit Loss
ProfitLoss
-31704000
us-gaap Profit Loss
ProfitLoss
-35874000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
134000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
189000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
96000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
385000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
5367000
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
116000
us-gaap Paid In Kind Interest
PaidInKindInterest
243000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-22000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
354000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
413000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
381000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1169000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
90000
us-gaap Share Based Compensation
ShareBasedCompensation
2407000
us-gaap Share Based Compensation
ShareBasedCompensation
4300000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
768000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-489000
svra Increase Decrease In Noncurrent Assets
IncreaseDecreaseInNoncurrentAssets
884000
svra Increase Decrease In Noncurrent Assets
IncreaseDecreaseInNoncurrentAssets
835000
svra Increase Decrease In Accounts Payable And Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities
-1485000
svra Increase Decrease In Accounts Payable And Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities
-1210000
svra Increase Decrease In Long Term Liabilities
IncreaseDecreaseInLongTermLiabilities
-118000
svra Increase Decrease In Long Term Liabilities
IncreaseDecreaseInLongTermLiabilities
-411000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30718000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27536000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
17000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
42000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
3247000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
138541000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
70157000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
67870000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
74100000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
2500000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
8780000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-68188000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
9434000
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
3909000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
514000
svra Proceeds From Issuance Of Common Stock And Pre Funded Warrants In Public Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts
122148000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2290000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
15000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
86000
svra Proceeds From Issuance Of Common Stock Upon Exercise Of Warrants Net
ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrantsNet
2546000
svra Proceeds From Issuance Of Common Stock Upon Exercise Of Warrants Net
ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrantsNet
1827000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
120800000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3689000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-75000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-172000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
21819000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14585000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22880000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
49804000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
44699000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
35219000
svra Common Stock Issued For Acquired In Process Research And Development
CommonStockIssuedForAcquiredInProcessResearchAndDevelopment
-2120000
svra Cash Paid For Interest Including End Of Period Charge Due Upon Long Term Debt Amendment
CashPaidForInterestIncludingEndOfPeriodChargeDueUponLongTermDebtAmendment
1469000
svra Cash Paid For Interest Including End Of Period Charge Due Upon Long Term Debt Amendment
CashPaidForInterestIncludingEndOfPeriodChargeDueUponLongTermDebtAmendment
1980000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-289200000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30700000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44700000
CY2021Q3 us-gaap Short Term Investments
ShortTermInvestments
126100000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Management’s estimates include, but are not limited to, those related to the accrual of research and development expenses and general and administrative costs, certain financial instruments recorded at fair value, contingent consideration, the valuation of stock-based compensation, and the valuation allowance for deferred tax assets. The Company bases its estimates on historical experience, changes in circumstance and facts, and on various other market-specific and relevant assumptions that it believes to be reasonable under the circumstances. Accordingly, actual results could be materially different from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents and foreign exchange derivatives not designated as hedging instruments. The Company places its cash and cash equivalents with a limited number of high-quality financial institutions and at times may exceed the amount of insurance provided on such deposits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q3 svra Prepaid Contracted Research And Development Costs
PrepaidContractedResearchAndDevelopmentCosts
2070000
CY2020Q4 svra Prepaid Contracted Research And Development Costs
PrepaidContractedResearchAndDevelopmentCosts
591000
CY2021Q3 svra Prepaid Research And Development Tax Credit Receivable
PrepaidResearchAndDevelopmentTaxCreditReceivable
888000
CY2020Q4 svra Prepaid Research And Development Tax Credit Receivable
PrepaidResearchAndDevelopmentTaxCreditReceivable
1042000
CY2021Q3 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
319000
CY2020Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
653000
CY2021Q3 us-gaap Prepaid Insurance
PrepaidInsurance
369000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
453000
CY2021Q3 svra Deposits And Other Assets Current
DepositsAndOtherAssetsCurrent
132000
CY2020Q4 svra Deposits And Other Assets Current
DepositsAndOtherAssetsCurrent
194000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3778000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2933000
CY2021Q3 svra Accrued Compensation
AccruedCompensation
2216000
CY2020Q4 svra Accrued Compensation
AccruedCompensation
1920000
CY2021Q3 svra Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
1902000
CY2020Q4 svra Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
2627000
CY2021Q3 svra Accrued General And Administrative Costs
AccruedGeneralAndAdministrativeCosts
931000
CY2020Q4 svra Accrued General And Administrative Costs
AccruedGeneralAndAdministrativeCosts
853000
CY2021Q3 svra Accrued Lease Liability
AccruedLeaseLiability
166000
CY2020Q4 svra Accrued Lease Liability
AccruedLeaseLiability
179000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5215000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5579000
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
126119000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
13000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
126107000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
59307000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
4000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
59308000
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2020Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2021Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
8333000
CY2020Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
8333000
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
18167000
CY2020Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
18167000
CY2021Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
26500000
CY2020Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
26500000
CY2021Q3 svra Unamortized End Of Term Charge
UnamortizedEndOfTermCharge
808000
CY2020Q4 svra Unamortized End Of Term Charge
UnamortizedEndOfTermCharge
1134000
CY2021Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
99000
CY2020Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
149000
CY2021Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
76000
CY2020Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
113000
CY2021Q3 us-gaap Long Term Debt
LongTermDebt
25517000
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
25104000
CY2021Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
4167000
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
21350000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
25104000
CY2020Q3 svra Upfront Cash Payment Payable
UpfrontCashPaymentPayable
3300000
svra Upfront Payment Common Stock Shares Issued
UpfrontPaymentCommonStockSharesIssued
1000000
svra Upfront Payment Common Stock Issued Value
UpfrontPaymentCommonStockIssuedValue
2100000
svra Increase Decrease In Process Research And Development Due To Foreign Currency Translation
IncreaseDecreaseInProcessResearchAndDevelopmentDueToForeignCurrencyTranslation
700000
svra Increase Decrease In Process Research And Development Due To Foreign Currency Translation
IncreaseDecreaseInProcessResearchAndDevelopmentDueToForeignCurrencyTranslation
500000
svra Proceeds From Issuance Of Common Stock And Pre Funded Warrants
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants
129968000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
7820000
svra Net Proceeds After Deducting Underwriting Discounts Commissions And Offering Expenses
NetProceedsAfterDeductingUnderwritingDiscountsCommissionsAndOfferingExpenses
122148000
CY2021Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
44315561
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
45133986
CY2021Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
38808502
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-17000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
959000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
942000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-657000
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
285000
svra Decrease In Milestone Payment Related To The Removal Of Nebulizer System
DecreaseInMilestonePaymentRelatedToTheRemovalOfNebulizerSystem
5000000
us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
2889000
CY2021Q3 svra Contingent Milestones Commitments Recognized
ContingentMilestonesCommitmentsRecognized
0
svra Research And Development Expense For Termination
ResearchAndDevelopmentExpenseForTermination
800000
CY2021Q1 svra Estimated Parexel Service Fees And Pass Through Expenses
EstimatedParexelServiceFeesAndPassThroughExpenses
32000000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6240343
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
509397
CY2020Q4 svra Share Based Compensation Arrangement By Share Based Payment Award Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber
6749740
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4541432
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
315625
CY2019Q4 svra Share Based Compensation Arrangement By Share Based Payment Award Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber
4857057
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
670000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
275000
svra Share Based Compensation Arrangement By Share Based Payment Award Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross
945000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
933639
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
227272
svra Share Based Compensation Arrangement By Share Based Payment Award Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGross
1160911
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
887278
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
212938
svra Share Based Compensation Arrangement By Share Based Payment Award Exercised In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisedInPeriod
1100216
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
64546
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
504647
CY2020Q3 svra Share Based Compensation Arrangement By Share Based Payment Award Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber
5193306
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
38250
svra Share Based Compensation Arrangement By Share Based Payment Award Exercised In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisedInPeriod
102796
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1044340
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
43125
svra Share Based Compensation Arrangement By Share Based Payment Award Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitedInPeriod
1087465
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
721866
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
0
svra Share Based Compensation Arrangement By Share Based Payment Award Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitedInPeriod
721866
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4978725
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
528334
CY2021Q3 svra Share Based Compensation Arrangement By Share Based Payment Award Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber
5507059
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4688659
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
690000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1931000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2407000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4300000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5584852
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
37022016
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-10546000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-11063000
us-gaap Net Income Loss
NetIncomeLoss
-31704000
us-gaap Net Income Loss
NetIncomeLoss
-35874000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10546000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11063000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-31704000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-35874000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-10546000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-11063000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-31704000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-35874000
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
152587848
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
60288993
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
127623824
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
58842436
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.61

Files In Submission

Name View Source Status
0000950170-21-004253-index-headers.html Edgar Link pending
0000950170-21-004253-index.html Edgar Link pending
0000950170-21-004253.txt Edgar Link pending
0000950170-21-004253-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
svra-20210930.htm Edgar Link pending
svra-20210930.xsd Edgar Link pending
svra-20210930_cal.xml Edgar Link unprocessable
svra-20210930_def.xml Edgar Link unprocessable
svra-20210930_htm.xml Edgar Link completed
svra-20210930_lab.xml Edgar Link unprocessable
svra-20210930_pre.xml Edgar Link unprocessable
svra-ex31_1.htm Edgar Link pending
svra-ex31_2.htm Edgar Link pending
svra-ex32_1.htm Edgar Link pending